VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced that a conference call will be held soon. This event aims to discuss the financial and operational results for the third quarter of the year. Interested participants can find all the information regarding this event outlined below.
Details of the Conference Call
The conference call is set to occur on Friday morning at 8:30 a.m. U.S. Eastern Time. This session will be led by key members of VolitionRX, including Louise Batchelor, Group Chief Marketing & Communications Officer, and Cameron Reynolds, President and Group Chief Executive Officer. They will be joined by Terig Hughes, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Dr. Andrew Retter, Chief Medical Officer.
This call will provide valuable insights into recent developments within the company and the milestones they aim to achieve. The executives plan to highlight significant events that have occurred during the third quarter and will also discuss future targets that the company is working towards.
How to Join the Call
For those wishing to participate in the call, they can dial in using the following numbers: U.S. & Canada Dial-in: 1-877-407-9716 (toll free), U.K. Dial-in: 0 800 756 3429 (toll free), and for international participants, the number is 1-201-493-6779.
About VolitionRX
Volition is a remarkable multi-national company concentrated on enhancing the field of epigenetics. Their mission revolves around saving lives and improving the conditions of both humans and animals suffering from serious diseases through timely detection and effective monitoring of treatment.
Through its various subsidiaries, Volition is advancing the development and marketing of straightforward, efficient, and affordable blood tests. These tests aim to assist healthcare providers by helping in the early diagnosis and ongoing monitoring of numerous diseases, particularly some cancers and conditions that involve NETosis, such as sepsis. Early detection is crucial as it can significantly extend the lifespan of patients and enhance their overall quality of life.
Global Presence and Research Activities
Volition's research and development efforts are largely driven from their facility in Belgium, while they maintain an innovative laboratory and an office in the United States. Additionally, the company operates other offices in various global locations, including London and Singapore, showcasing its commitment to worldwide healthcare improvement.
Frequently Asked Questions
What is the date of the upcoming earnings call for VolitionRx?
The upcoming earnings call for VolitionRx Limited is scheduled for Friday at 8:30 a.m. U.S. Eastern Time.
Who will be hosting the earnings call?
The call will be hosted by Louise Batchelor and attended by senior executives including Cameron Reynolds and Terig Hughes.
What topics will be covered during the earnings call?
The earnings call will cover financial results, operational updates, and important milestones for the third quarter of 2024.
How can I participate in the earnings call?
Participants can join the call by dialing a designated toll-free number provided for U.S., U.K., and international callers.
What is the primary focus of VolitionRx as a company?
VolitionRx focuses on advancing the science of epigenetics and developing cost-effective blood tests for early disease diagnosis and monitoring.
